BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26349665)

  • 21. [Clinical value of combined detection with urinary bladder cancer antigen, hyaluronic acid and cytokeratin 20 in diagnosis of bladder cancer].
    Pu XY; Wang ZP; Chen YR; Wu YL; Wang HP; Wang XH
    Ai Zheng; 2008 Sep; 27(9):970-3. PubMed ID: 18799038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A panel of angiogenic factors for early bladder cancer detection: enzyme immunoassay and Western blot.
    Eissa S; Swellam M; Labib RA; El-Zayat T; El Ahmady O
    J Urol; 2009 Mar; 181(3):1353-60. PubMed ID: 19185322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection.
    Park HS; Park WS; Bondaruk J; Tanaka N; Katayama H; Lee S; Spiess PE; Steinberg JR; Wang Z; Katz RL; Dinney C; Elias KJ; Lotan Y; Naeem RC; Baggerly K; Sen S; Grossman HB; Czerniak B
    J Natl Cancer Inst; 2008 Oct; 100(19):1401-11. PubMed ID: 18812553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
    Liu H; He W; Wang B; Xu K; Han J; Zheng J; Ren J; Shao L; Bo S; Lu S; Lin T; Huang J
    BMC Cancer; 2018 Jun; 18(1):659. PubMed ID: 29907142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
    Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
    Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Significance of Serological and Urological Levels of Bladder Cancer-Specific Antigen-1 (BLCA-1) in Bladder Cancer.
    Wang Z; Li H; Chi Q; Qiu Y; Li X; Xin L
    Med Sci Monit; 2018 Jun; 24():3882-3887. PubMed ID: 29883442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating levels and clinical implications of epithelial membrane antigen and cytokeratin-1 in women with breast cancer: can their ratio improve the results?
    Attallah AM; El-Far M; Omran MM; Abdallah SO; El-Desouky MA; El-Dosoky I; Abdelrazek MA; Attallah AA; Elweresh MA; Abdel Hameed GE; Shawki HA; Salama KS; El-Waseef AM
    Tumour Biol; 2014 Nov; 35(11):10737-45. PubMed ID: 25073515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunocytochemically demonstrated expression of epithelial membrane antigen and carcinoembryonic antigen by exfoliated urinary cells in patients with bladder cancer.
    Tanaka K; Takashi M; Miyake K; Koshikawa T
    Urol Int; 1994; 52(3):140-4. PubMed ID: 8203052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma.
    Todenhöfer T; Hennenlotter J; Esser M; Mohrhardt S; Tews V; Aufderklamm S; Gakis G; Kuehs U; Stenzl A; Schwentner C
    Cancer Cytopathol; 2013 May; 121(5):252-60. PubMed ID: 23172833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
    Jamshidian H; Kor K; Djalali M
    Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urinary modified nucleosides as novel biomarkers for diagnosis and prognostic monitoring of urothelial bladder cancer.
    Zhang YR; Shi L; Wu H; Tang DD; Wang SM; Liu HM; Zhang LR; Song DK
    Tumori; 2014; 100(6):660-6. PubMed ID: 25688500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer.
    Fantony JJ; Abern MR; Gopalakrishna A; Owusu R; Jack Tay K; Lance RS; Inman BA
    Urol Oncol; 2015 Sep; 33(9):387.e1-6. PubMed ID: 26027762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
    Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive values of urinary bladder tumor markers survivin and soluble-Fas comparison with cystoscopy and bladder tumor antigen.
    Ganas V; Kalaitzis C; Sountoulides P; Giannakopoulos S; Touloupidis S
    Minerva Urol Nefrol; 2012 Dec; 64(4):279-85. PubMed ID: 23288215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma.
    Passerotti CC; Srougi M; Bomfim AC; Martins JR; Leite KR; Dos Reis ST; Sampaio LO; Ortiz V; Dietrich CP; Nader HB
    Urol Oncol; 2011; 29(6):710-5. PubMed ID: 19962919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical performance and utility of a NNMT-based urine test for bladder cancer.
    Pozzi V; Di Ruscio G; Sartini D; Campagna R; Seta R; Fulvi P; Vici A; Milanese G; Brandoni G; Galosi AB; Montironi R; Cecati M; Emanuelli M
    Int J Biol Markers; 2018 Jan; 33(1):94-101. PubMed ID: 29148015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
    Eissa S; Ali-Labib R; Swellam M; Bassiony M; Tash F; El-Zayat TM
    Eur Urol; 2007 Nov; 52(5):1388-96. PubMed ID: 17466450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of urinary bladder cancer antigen as a marker for diagnosis of transitional cell carcinoma of the urinary bladder.
    Heicappell R; Schostak M; Müller M; Miller K
    Scand J Clin Lab Invest; 2000 Jul; 60(4):275-82. PubMed ID: 10943597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HCC-DETECT: a combination of nuclear, cytoplasmic, and oncofetal proteins as biomarkers for hepatocellular carcinoma.
    Attallah AM; El-Far M; Malak CA; Omran MM; Shiha GE; Farid K; Barakat LA; Albannan MS; Attallah AA; Abdelrazek MA; Elbendary MS; Sabry R; Hamoda GA; Elshemy MM; Ragab AA; Foda BM; Abdallah SO
    Tumour Biol; 2015 Sep; 36(10):7667-74. PubMed ID: 25929809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary retinoic acid receptor-β2 gene promoter methylation and hyaluronidase activity as noninvasive tests for diagnosis of bladder cancer.
    Eissa S; Zohny SF; Shehata HH; Hegazy MG; Salem AM; Esmat M
    Clin Biochem; 2012 Apr; 45(6):402-7. PubMed ID: 22286019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.